TABLE 3.
The ameliorative effect of berberine on sepsis and viral infections.
| Experimental model | Role of berberine | Molecular mechanism involeves | Outcome of the study | References |
| LPS-induced ALI C57BL/6 mice | Anti-inflammatory; Protected against lung injury | Inhibition of p-NF-κB/NLRP3 signaling pathway; Blocking effects of NLRP3 | Suppressed IL-1β, IL-18, IL-6, TNF-α; Promoted IL-10 | Chen et al. (2022) |
| LPS-induced endotoxemic BALB/c mice | Anti-inflammatory, Reduced the severity of organ injury | Activation of AMPK-P38/MAPK; Inhibition of p-P65,p-IκBα, | Suppressed HMGB1; Reduced iNOS | Lee et al. (2017) |
| LPS plus D-galactosamine-induced sepsis C57BL/6 mice | Anti-inflammatory; Protected against ALI; Improved the survival rate of septic mice | Inhibition of p-IKKα/β, p-IκB, P65; Inhibition of p-STAT3, KIF4, Myc | Suppressed IL-1β, IL-6, TNF-α | Wang et al. (2020) |
| CLP-induced SAE C57BL/6 mice | Anti-inflammatory; Antioxidant; Alleviated sepsis-induced cognitive impairment | Inhibition of HMGB1/RAGE signaling | Reduced expression of TNF-α, IL-1α | Shi et al. (2021) |
| CS-induced NS C57BL/6 mice | Anti-inflammatory; Increased the survival rates; Reduced the intestinal injurie | Increase the level of miR-132-3p;Inhibition of FOXA1, p-IκBα,P65 | Suppressed IL-1β, IL-6, TNF-α | Li et al., 2021 |
| CLP-induced polymicrobial sepsis SD rats | Anti-inflammatory; Attenuated tissue injury | Reduced expression of TLR2, TLR4; Increased expression of TLR9; Inhibition of NF-κB | Reduced expression of TNF-α, IL-6 | Li et al. (2015a) |
| LPS-induced SCM SD rats | Anti-inflammatory; Reduced the myocardial injury | Reduced expression of TLR4; Inhibition of P65 | Suppressed IL-1β, TNF-α | Li et al. (2015a) |
| CLP-induced sepsis Kunming mice | Attenuated neutrophil tissue infiltration and multiorgan dysfunction | Promoted IL-10; Reduced expression of CCR2 | Decreased MPO; Increased expression of KC, MCP-1, MIP-1, MIP-2 | Wang et al. (2016) |
| LPS-induced sepsis BALB/c mice | Attenuated neutrophil tissue; Protected against lung injury; Increased the survival rates | Reduced expression of cPLA2,p-cPLA2 | Reduced expression of TNF-α | Zhang et al., 2008 |
| A/FM1/1/47 (H1N1) influenza virus-infected C57BL/6 mice | Anti-viral; Anti-inflammatory, Reduced lung injury | Reduced expression of TLR7, MyD88, P65/NF-κB | Suppressed IFN-γ, IL-1β, TNF-α; Promoted IL-4; decreased the ratios of Th1/Th2 and Th17/Treg cells | Zhang et al., 2008 |
| 10LD50 influenza virus-infected BALb/c mice | Anti-viral; Anti-inflammatory, Reduced tissue damage | Promoted expression of LC3, BNIP3; inhibited mtROS generation | Reduced expression of NLRP3; Suppressed caspase-1 activation; Suppressed IL-1β; Up-regulated mitophagy | Liu et al. (2020) |
| Poly I:C-induced RAW 264.7 cells | Anti-apoptosis; Anti-inflammatory | Reduced expression of p-P38, p-ERK 1/2, p-STAT3, p-IkBα | Suppressed NO, PGE2, Fas, GM-CSF, LIF, LIX, RANTES, MIP-2 | Kim et al. (2021a) |
| COVID-19 spike protein-induced SK-N-SH and CCD-841 CoN cells | Anti-inflammatory; Enhanced cell activity | — | Suppressed TNF-α, IL-6 | Gu et al. (2021) |
Note: ALI, acute lung injury; KLF-4, Krüppel-like factor 4; CLP, caecal ligation and puncture; SAE, sepsis-associated encephalopathy; CS, cecal slurry; NS, neonatal sepsis; SCM, septic cardiomyopathy; CCR2, Chemokine Receptor 2; KC, keratinocyte-derived chemokine; MIP-1, macrophage inflammatory protein-1; MIP-2, macrophage inflammatory protein-2; MCP-1, monocyte chemoattractant protein-1; cPLA2, cytosolic phospholipase A2; Poly I:C, polyinosinic-polycytidylic acid; PGE2, Prostaglandin E2, Fas: first apoptosis signal receptor; GM-CSF, granulocyte macrophage colony-stimulating factor; LIF, leukemia inhibitory factor; LIX, lipopolysaccharide-induced CXC, chemokine; RANTES, chemokine ligand 5 (Ye et al., 2020).